Jafer C.P.,Al Shifa Hospital Perinthalmanna |
Veena R.,Mahatma Gandhi University
Research Journal of Pharmaceutical, Biological and Chemical Sciences | Year: 2014
The antidiabetic drug Pioglitazone belongs to the group of Glitazones having thiazolidinedione structure. Glitazones are believed to have a role in in ß cell protection of pancreas and help to decrease triglycerides and increase high density lipoprotein cholesterol (HDL-C). They are hepatically metabolised and hence can be used in patients with renal dysfunction. Glitazones help to reduce blood glucose and HbA1c without increasing circulating insulin. Pioglitazone was introduced in Indian market in 2001 both as single and combination products with metformin, glimepiride and alogliptin. By 2012 pioglitazone became one of the fast moving prescription drugs in the country and its sale exceeded 600 crore (6000 million) INR. The Government of India suspended the manufacture, sale and distribution of pioglitazone with immediate effect through a gazette notification on 18th June 2013 because of its association with bladder cancer. On 31st July 2013, through another surprise notification, Government of India revoked the suspension and allowed pioglitazone to be marketed in India subject to certain conditions the manufacturers shall mention on its patient package inserts and promotional literature. By 2014 January, the sale of pioglitazone got reduced to 15-20 per cent of its sale in January 2013 in India. The study shows how drastically the incidence of pioglitazone prescriptions got reduced in the state of Kerala and highlights the need for scientific studies on Indian people.